Viyash Scientific per share figures

Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
₹4.19₹4.09₹0.88−₹1.44−₹4.88
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
₹4.09₹4.01₹0.85−₹1.44−₹4.88
₹66.64₹66.64₹28.15₹26.32₹28.01
₹72.08₹78.29₹61.98₹54.91₹56.97
—₹7.39₹3.33₹1.23₹0.67
₹4.31₹4.31₹1.77−₹0.01−₹2.78
—₹0.11₹0.07₹0.00₹0.00
43.743.725.024.924.9
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

VIYASH₹204.52

Viyash Scientific Ltd.

· Pharma & Health
₹ CrorePeersAARTIDRUGSYATHARTHTHYROCARESUPRIYASTARSPARCSHILPAMEDRUBICONMcap ₹8,934 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
₹ per share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Basic EPS-4.88-1.440.884.094.19
Diluted EPS-4.88-1.440.854.014.09
Book Value per Share28.0126.3228.1566.6466.64
Revenue per Share56.9754.9161.9878.2972.08
Cash Flow per Share0.671.233.337.39—
Free Cash Flow per Share-2.78-0.011.774.314.31
Dividends per Share0.000.000.070.11—
Shares Outstanding (cr)24.924.925.043.743.7
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.